U.S. markets open in 3 hours 52 minutes
  • S&P Futures

    4,018.50
    -14.00 (-0.35%)
     
  • Dow Futures

    33,688.00
    -97.00 (-0.29%)
     
  • Nasdaq Futures

    11,905.00
    -63.00 (-0.53%)
     
  • Russell 2000 Futures

    1,888.00
    -5.50 (-0.29%)
     
  • Crude Oil

    76.62
    -1.28 (-1.64%)
     
  • Gold

    1,920.50
    -18.70 (-0.96%)
     
  • Silver

    23.20
    -0.53 (-2.22%)
     
  • EUR/USD

    1.0830
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    3.5510
    0.0000 (0.00%)
     
  • Vix

    20.50
    +1.99 (+10.75%)
     
  • GBP/USD

    1.2312
    -0.0042 (-0.34%)
     
  • USD/JPY

    130.4100
    +0.0520 (+0.04%)
     
  • BTC-USD

    22,914.35
    -376.66 (-1.62%)
     
  • CMC Crypto 200

    519.63
    -18.25 (-3.39%)
     
  • FTSE 100

    7,729.08
    -55.79 (-0.72%)
     
  • Nikkei 225

    27,327.11
    -106.29 (-0.39%)
     

Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings

  • Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of Roche Holdings AG (OTC: RHHBY) for respiratory and ophthalmology.

  • The research collaboration will utilize Pieris' Anticalin technology, initially for respiratory disease and ophthalmology, with an opportunity to nominate additional programs.

  • Under the agreement terms, Pieris will receive $20 million as an upfront payment, eligible to receive more than $1.4 billion in additional milestone payments and tiered royalties.

  • Pieris will be responsible for discovery research and early preclinical development of the programs, and Genentech will be responsible for IND-enabling activities, clinical development, and commercialization of those programs.

  • Genentech will also have the option to select additional targets in return for an option exercise fee.

  • Price Action: PIRS shares are up 49.3% at $2.76 on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.